Clinical Trial Update: PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated pegylated interferon alfa-2b in patients with surgically resectable stage II–IV head and neck cancer, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED